CTOs on the Move

K-LaB Technologies

www.klabtech.com

 
K-LaB Technologies, Inc. is a Dripping Springs, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.klabtech.com
  • 600 Winchester Dr
    Dripping Springs, TX USA 78620
  • Phone: 310.432.6400

Executives

Name Title Contact Details

Similar Companies

Humanetics

Humanetics Corp. is a Eden Prairie, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

QED Therapeutics

QED Therapeutics, a subsidiary of BridgeBio Pharma, is a biotechnology company focused on precision medicine for FGFR-driven disorders.

AgriThority

AgriThority® is the first independent data-through-delivery product and market development company in the agriculture industry. Instead of delivering a “data dump” and walking away, AgriThority® assimilates and summarizes data to ensure you get the consistency and continuity your project demands. Producers benefit, too. AgriThority® has unmatched strength in the development of best management practices (BMPs) in animal health, agronomic and horticultural crop production, and in the development of product use within those BMPs. AgriThority® further builds trust and credibility for products and innovations by providing and delivering training and educational programs for company sales and field development organizations, technical influencers, channel partners and producers.

Evolve Biosystems

Evolve BioSystems is a spin-out from the Foods For Health Institute (FFHI) at the University of California, Davis. The company builds on more than a decade of research into the infant gut microbiome and its unique interaction with breast milk components, established by the founding scientists including Bruce German, David Mills, Carlito Lebrilla, Daniela Barile and Samara Freeman. Their fundamental research and translational clinical trials have been enabled by more than $15 million in federal and private grants since 2004. Under the leadership of CEO Dr. David Kyle, Evolve completed a $1 million seed funding round in mid-2014, a $9 million Series A round in August 2015 and most recently a $20 million Series B capital raise in 2017. Evolve has now successfully completed a milestone proof-of-concept study to demonstrate the efficacy of its initial proprietary offering, with a series of upcoming trials scheduled across both human and animal health applications. With a strong portfolio of intellectual property developed at UC Davis, a world-class management team plus blue-chip investors, and an unwavering dedication to allowing science to direct our product development, Evolve continues to expand it`s pipeline of next generation microbiome-based solutions to establish, restore, and maintain a healthy gut microbiome.

Orphan Star Therapeutics

Orphan Star Therapeutics, LLC, a biopharmaceutical company, develops therapies for rare genetic diseases including Canavan disease, glut1 deficiency, and rare genetic skin diseases.